GroundRules
Browse Federal regulations
Read the original sections, or search by topic.
- 21 CFR 189.300 · Hydrogenated 4,4′-isopropylidene-diphenolphosphite ester resins.
- 21 CFR 189.301 · Tin-coated lead foil capsules for wine bottles.
- 21 CFR 190.6 · Requirement for premarket notification.
- 21 CFR 200.5 · Mailing of important information about drugs.
- 21 CFR 200.7 · Supplying pharmacists with indications and dosage information.
- 21 CFR 200.10 · Contract facilities (including consulting laboratories) utilized as extramural facilities by pharmaceutical manufacturers.
- 21 CFR 200.11 · Use of octadecylamine in steam lines of drug establishments.
- 21 CFR 200.15 · Definition of term “insulin.”
- 21 CFR 200.50 · Ophthalmic preparations and dispensers.
- 21 CFR 200.51 · Aqueous-based drug products for oral inhalation.
- 21 CFR 200.200 · Prescription drugs; reminder advertisements and reminder labeling to provide price information to consumers.
- 21 CFR 201.1 · Drugs; name and place of business of manufacturer, packer, or distributor.
- 21 CFR 201.2 · Drugs and devices; National Drug Code numbers.
- 21 CFR 201.5 · Drugs; adequate directions for use.
- 21 CFR 201.6 · Drugs; misleading statements.
- 21 CFR 201.10 · Drugs; statement of ingredients.
- 21 CFR 201.15 · Drugs; prominence of required label statements.
- 21 CFR 201.16 · Drugs; Spanish-language version of certain required statements.
- 21 CFR 201.17 · Drugs; location of expiration date.
- 21 CFR 201.18 · Drugs; significance of control numbers.
- 21 CFR 201.19 · Drugs; use of term “infant”.
- 21 CFR 201.20 · Declaration of presence of FD&C Yellow No. 5 and/or FD&C Yellow No. 6 in certain drugs for human use.
- 21 CFR 201.21 · Declaration of presence of phenylalanine as a component of aspartame in over-the-counter and prescription drugs for human use.
- 21 CFR 201.22 · Prescription drugs containing sulfites; required warning statements.
- 21 CFR 201.23 · Required pediatric studies.
- 21 CFR 201.24 · Labeling for systemic antibacterial drug products.
- 21 CFR 201.25 · Bar code label requirements.
- 21 CFR 201.26 · Exceptions or alternatives to labeling requirements for human drug products held by the Strategic National Stockpile.
- 21 CFR 201.50 · Statement of identity.
- 21 CFR 201.51 · Declaration of net quantity of contents.
- 21 CFR 201.55 · Statement of dosage.
- 21 CFR 201.56 · Requirements on content and format of labeling for human prescription drug and biological products.
- 21 CFR 201.57 · Specific requirements on content and format of labeling for human prescription drug and biological products described in § 201.56(b)(1).
- 21 CFR 201.58 · Waiver of labeling requirements.
- 21 CFR 201.60 · Principal display panel.
- 21 CFR 201.61 · Statement of identity.
- 21 CFR 201.62 · Declaration of net quantity of contents.
- 21 CFR 201.63 · Pregnancy/breast-feeding warning.
- 21 CFR 201.64 · Sodium labeling.
- 21 CFR 201.66 · Format and content requirements for over-the-counter (OTC) drug product labeling.
- 21 CFR 201.67 · Labeling requirements for a nonprescription drug product with an additional condition for nonprescription use (ACNU).
- 21 CFR 201.70 · Calcium labeling.
- 21 CFR 201.71 · Magnesium labeling.
- 21 CFR 201.72 · Potassium labeling.
- 21 CFR 201.80 · Specific requirements on content and format of labeling for human prescription drug and biological products; older drugs not described in § 201.56(b)(1).
- 21 CFR 201.100 · Prescription drugs for human use.
- 21 CFR 201.105 · Veterinary drugs.
- 21 CFR 201.115 · New drugs or new animal drugs.
- 21 CFR 201.116 · Drugs having commonly known directions.
- 21 CFR 201.117 · Inactive ingredients.
- 21 CFR 201.119 · In vitro diagnostic products.
- 21 CFR 201.120 · Prescription chemicals and other prescription components.
- 21 CFR 201.122 · Drugs for processing, repacking, or manufacturing.
- 21 CFR 201.125 · Drugs for use in teaching, law enforcement, research, and analysis.
- 21 CFR 201.127 · Drugs; expiration of exemptions.
- 21 CFR 201.128 · Meaning of “intended uses”.
- 21 CFR 201.129 · Drugs; exemption for radioactive drugs for research use.
- 21 CFR 201.130 · Exemption from adequate directions for use for a nonprescription drug product with an additional condition for nonprescription use (ACNU).
- 21 CFR 201.150 · Drugs; processing, labeling, or repacking.
- 21 CFR 201.161 · Medical gases.
- 21 CFR 201.200 · Disclosure of drug efficacy study evaluations in labeling and advertising.
- 21 CFR 201.300 · Notice to manufacturers, packers, and distributors of glandular preparations.
- 21 CFR 201.301 · Notice to manufacturers, packers, and distributors of estrogenic hormone preparations.
- 21 CFR 201.302 · Notice to manufacturers, packers, and distributors of drugs for internal use which contain mineral oil.
- 21 CFR 201.303 · Labeling of drug preparations containing significant proportions of wintergreen oil.
- 21 CFR 201.304 · Tannic acid and barium enema preparations.
- 21 CFR 201.305 · Isoproterenol inhalation preparations (pressurized aerosols, nebulizers, powders) for human use; warnings.
- 21 CFR 201.306 · Potassium salt preparations intended for oral ingestion by man.
- 21 CFR 201.307 · Sodium phosphates; package size limitation, warnings, and directions for over-the-counter sale.
- 21 CFR 201.308 · Ipecac syrup; warnings and directions for use for over-the-counter sale.
- 21 CFR 201.309 · Acetophenetidin (phenacetin)-containing preparations; necessary warning statement.
- 21 CFR 201.310 · Phenindione; labeling of drug preparations intended for use by man.
- 21 CFR 201.311 · [Reserved]
- 21 CFR 201.312 · Magnesium sulfate heptahydrate; label declaration on drug products.
- 21 CFR 201.313 · Estradiol labeling.
- 21 CFR 201.314 · Labeling of drug preparations containing salicylates.
- 21 CFR 201.315 · Over-the-counter drugs for minor sore throats; suggested warning.
- 21 CFR 201.316 · Drugs with thyroid hormone activity for human use; required warning.
- 21 CFR 201.317 · Digitalis and related cardiotonic drugs for human use in oral dosage forms; required warning.
- 21 CFR 201.319 · Water-soluble gums, hydrophilic gums, and hydrophilic mucilloids (including, but not limited to agar, alginic acid, calcium polycarbophil, carboxymethylcellulose sodium, carrageenan, chondrus, glucomannan ((B-1,4 linked) polymannose acetate), guar gum, karaya gum, kelp, methylcellulose, plantago seed (psyllium), polycarbophil tragacanth, and xanthan gum) as active ingredients; required warnings and directions.
- 21 CFR 201.320 · Warning statements for drug products containing or manufactured with chlorofluorocarbons or other ozone-depleting substances.
- 21 CFR 201.323 · Aluminum in large and small volume parenterals used in total parenteral nutrition.
- 21 CFR 201.325 · Over-the-counter drugs for vaginal contraceptive and spermicide use containing nonoxynol 9 as the active ingredient; required warnings and labeling information.
- 21 CFR 201.326 · Over-the-counter drug products containing internal analgesic/antipyretic active ingredients; required warnings and other labeling.
- 21 CFR 201.327 · Over-the-counter sunscreen drug products; required labeling based on effectiveness testing.
- 21 CFR 201.328 · Labeling of medical gas containers.
- 21 CFR Appendix A to Part 201 · Appendix A to Part 201—Examples of Graphic Enhancements Used by FDA
- 21 CFR 202.1 · Prescription-drug advertisements.
- 21 CFR 203.1 · Scope.
- 21 CFR 203.2 · Purpose.
- 21 CFR 203.3 · Definitions.
- 21 CFR 203.10 · Restrictions on reimportation.
- 21 CFR 203.11 · Applications for reimportation to provide emergency medical care.
- 21 CFR 203.12 · An appeal from an adverse decision by the district office.
- 21 CFR 203.20 · Sales restrictions.
- 21 CFR 203.22 · Exclusions.
- 21 CFR 203.23 · Returns.
- 21 CFR 203.30 · Sample distribution by mail or common carrier.
- 21 CFR 203.31 · Sample distribution by means other than mail or common carrier (direct delivery by a representative or detailer).
- 21 CFR 203.32 · Drug sample storage and handling requirements.